Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Fractyl Health, Inc. Common Stock GUTS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.00
+825.9%

Fractyl Health, Inc. Common Stock (GUTS) is a Biotechnology company in the Healthcare sector, currently trading at $0.54. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is GUTS = $5 (+825.9% upside).

Valuation: GUTS trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.

Net income is $141M (loss), growing at -53.4%/yr. Net profit margin is 0% (thin). Gross margin is 46.2% (+10.4 pp trend).

Balance sheet: total debt is $62M against $9M equity (Debt-to-Equity (D/E) ratio 6.52, leveraged). Current ratio is 4.78 (strong liquidity). Debt-to-assets is 50.8%. Total assets: $121M.

Analyst outlook: 2 / 3 analysts rate GUTS as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 43/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$5.00
▲ 825.93% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for Fractyl Health, Inc. Common Stock, the average price target is $5.00, with a high forecast of $8.00, and a low forecast of $2.00.
Highest Price Target
$8.00
Average Price Target
$5.00
Lowest Price Target
$2.00

GUTS SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GUTS

✓
VALUE Pass
100/100
GUTS trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25). Forward PEG 0.02 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.08. Analyst consensus target is $5, implying +825.9% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GUTS: -61.3%/yr revenue is, -53.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet GUTS: Debt-to-Equity (D/E) ratio 6.52 (leveraged), Current ratio is 4.78 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
43/100
GUTS: Gross margin is 46.2% (+10.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 2 / 3 analysts rate GUTS as buy (67%). Analyst consensus target is $5 (+825.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.377-3.03
Volume1.44M
Avg Volume (30D)5.42M
Market Cap$38.98M
Beta (1Y)1.19
Share Statistics
EPS (TTM)-1.86
Shares Outstanding$75.82M
IPO Date2024-02-02
Employees107
CEOHarith Rajagopalan
Financial Highlights & Ratios
Gross Profit$-1.13M
EBITDA$-95.69M
Net Income$-140.95M
Operating Income$-96.82M
Total Cash$81.54M
Total Debt$61.65M
Net Debt$-19.89M
Total Assets$121.4M
Price / Earnings (P/E)-0.3
Analyst Forecast
1Y Price Target$5.00
Target High$8.00
Target Low$2.00
Upside+825.9%
Rating ConsensusBuy
Analysts Covering3
Buy 67% Hold 33% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS35168W1036

Price Chart

Track all markets on TradingView
GUTS
Fractyl Health, Inc. Common Stock ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.38 52WK RANGE 3.03

People Also View

STRO
STRO
Sutro Biopharma, Inc.
$29.77
+3.44%
 ARTV
ARTV
Artiva Biotherapeutics, Inc.
$9.10
+21.50%
 BMEA
BMEA
Biomea Fusion, Inc.
$1.97
+1.03%
 RPTX
RPTX
Repare Therapeutics Inc.
$2.65
+0.00%
 DTIL
DTIL
Precision BioSciences, Inc.
$7.66
+5.95%
 ADVM
ADVM
Adverum Biotechnologies, Inc.
$4.36
+0.00%
 ALXO
ALXO
ALX Oncology Holdings Inc.
$1.68
+4.02%
 ATYR
ATYR
aTyr Pharma, Inc.
$0.86
+1.71%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message